Publications by authors named "Yu-Xi Qin"

Article Synopsis
  • This study focuses on developing inhibitors for deoxyhypusine synthase (DHPS), which is crucial for targeting vasculogenic mimicry (VM) in malignant melanoma, a factor linked to poor patient outcomes.
  • A new compound, 7k, was identified as effective in inhibiting DHPS activity and was shown to affect the expression of specific genes involved in VM, contributing to its anti-melanoma properties.
  • Testing in zebrafish and various models shows that 7k not only impacts melanoma cell behavior but also demonstrates significant effectiveness against melanoma growth, revealing DHPS as a vital target for treatment.
View Article and Find Full Text PDF
Article Synopsis
  • Discovering new melanoma treatments is crucial for improving human health, with a focus on the role of deoxyhypusine synthase (DHPS) in tumor development.
  • Studies show that DHPS regulates m6A modification and mRNA stability in melanoma by activating eIF5A, which helps the METTL3 enzyme modify mRNA.
  • A new compound, GL-1, has been identified as a DHPS inhibitor that promotes cancer cell death and shows potential for effective melanoma treatment in preliminary studies.
View Article and Find Full Text PDF

The discovery of new therapeutic strategies for diseases is essential for drug research. Deoxyhypusine synthase (DHPS) is a critical enzyme that modifies the conversion of the eukaryotic translation initiation factor 5A (eIF5A) precursor into physiologically active eIF5A (eIF5A-Hyp). Recent studies have revealed that the hypusine modifying of DHPS on eIF5A has an essential regulatory role in human diseases.

View Article and Find Full Text PDF

Study Design: International multicentre cross-sectional study.

Objectives: To describe the organisation and systems of paediatric spinal cord injury (SCI) rehabilitation services in seven countries and compare them with available recommendations and key features of paediatric SCI.

Setting: Ten SCI rehabilitation units in seven countries admitting children and adolescents with SCI < 18 years of age.

View Article and Find Full Text PDF